IASLC World Conference on Lung Cancer | Conference

Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC

August 6th 2022

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

Sacituzumab Govitecan Under Further Exploration in Pretreated Metastatic NSCLC

August 6th 2022

The antibody-drug conjugate sacituzumab govitecan will be evaluated vs single-agent docetaxel during the phase 3 EVOKE-01 trial in patients with metastatic non–small cell lung cancer.

Osimertinib/Savolitinib Combo Looks to Overcome Acquired Resistance in EGFR-Mutant NSCLC

August 5th 2022

Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.

Eftilagimod Alpha/Pembrolizumab Combo Elicits Encouraging Survival Benefits in Anti–PD-1/PD-L1 Refractory NSCLC

August 2nd 2022

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.

Karen L. Kelly, MD, Named IASLC Chief Executive Officer of the International Association for the Study of Lung Cancer

December 20th 2021

The Board of Directors of the International Association for the Study of Lung Cancer is pleased to announce the appointment of Karen L. Kelly, M.D. to the position of Chief Executive Officer, effective Spring 2022.

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC

September 15th 2021

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Clinical Response to Sotorasib May Vary By Genomic Profile in NSCLC

September 14th 2021

The clinical response to sotorasib could vary in patients with KRAS G12C–mutated non–small cell lung cancer depending on their co-mutational status.

Novel Neoadjuvant Triplet Shows Preliminary Promise in Resectable Pleural Mesothelioma

September 13th 2021

Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab, followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma.

Mobocertinib Elicits Antitumor Activity in EGFR Exon 20 Insertion+ NSCLC After Disease Control With EGFR TKIs

September 13th 2021

Mobocertinib was found to provide a meaningful clinical benefit with acceptable tolerability in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer who had previously achieved disease control of 6 months or longer with EGFR TKIs.

Mobocertinib Plus T-DM1 Elicits Preclinical Activity in HER2 Exon 20 Insertion+ Lung Cancer Models

September 13th 2021

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC

September 11th 2021

Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer Mortality Rates in the United States

September 11th 2021

Raymond U. Osarogiagbon, MD, discusses geographic disparities in lung cancer mortality rates across the United States.

Sequential Crizotinib Followed by Alectinib Associated With Survival Benefit in ALK+ NSCLC

September 11th 2021

Frontline sequential therapy with crizotinib followed by alectinib demonstrated survival benefits for patients with ALK-positive non–small cell lung cancer who develop resistance to, or become intolerant of crizotinib.

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung Cancer

September 10th 2021

Makenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

September 10th 2021

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

September 9th 2021

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies

September 9th 2021

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

Flexible Approaches Could Help to Increase Lung Cancer Clinical Trial Enrollment During COVID-19 Pandemic

September 9th 2021

Flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation in international lung cancer clinical trials.

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

September 9th 2021

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.